These ASX 200 blue chip shares could rise 25% to 40%

Analysts are bullish on these big names. Let's see what they are recommending.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear, a leader in hearing devices, is recommended by UBS due to its dominant market share and growth potential, with a projected 30% upside as it continues to innovate and expand product offerings.
  • CSL, despite recent pressures from its Seqirus spin-off and regulatory concerns, remains a strong investment due to its robust demand and strategic investments in plasma collection and therapy development, with Morgans forecasting a nearly 40% rise.
  • REA Group, dominating Australia's online property advertising, is expanding into financial services and data products, with Bell Potter suggesting a 25% upside, benefiting from potential interest rate cuts and its strategic market positioning.

Blue chip shares are often the cornerstone of long-term portfolios. They offer stability, strong market positions, and the ability to grow earnings through multiple economic cycles.

And with recent volatility pulling several high-quality names down meaningfully, analysts see buying opportunities emerging across the ASX 200.

For example, here are three ASX 200 blue chip shares that brokers have flagged as top buys right now. They are as follows:

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

Cochlear Ltd (ASX: COH)

Cochlear could be an ASX 200 blue chip share to buy. It is a leader in implantable hearing devices globally. Demand for its products continues to rise as ageing populations grow and access to hearing treatments expands worldwide.

The company's ongoing investment in research and new product development has helped it maintain its dominant market share and support steady revenue growth. And with a strong balance sheet, rising volumes, and a history of delivering consistent earnings and dividends, Cochlear continues to stand out as a reliable long-term compounder.

UBS is a fan of the company and has a buy rating and a $350.00 price target on the stock. This implies around 30% upside from current levels.

CSL Ltd (ASX: CSL)

Global biotech heavyweight CSL has come under pressure in recent months, with investor sentiment dampened by the planned Seqirus spin-off, regulatory uncertainty, and a slower-than-hoped recovery in plasma margins. But despite recent share price weakness, CSL's long-term fundamentals remain strong.

CSL continues to invest in expanding its plasma collection network, developing new therapies, and strengthening its manufacturing footprint in the United States. Demand for its core plasma-derived products remains robust, and analysts expect earnings momentum to rebuild as temporary headwinds ease.

So, with its shares trading close to a 52-week low, CSL's valuation looks significantly more appealing than it has in years.

Morgans sees meaningful upside from current levels. It has a buy rating and a $249.51 price target on its shares, which suggests that they could rise almost 40%.

REA Group Ltd (ASX: REA)

Finally, REA Group could be an ASX 200 blue chip share to buy now. It dominates Australia's online property advertising market, supported by powerful pricing power, strong customer relationships, and significant digital scale.

It has also expanded beyond listings into financial services, data products, and international investments, broadening its growth runway. With more interest rate cuts potentially coming in 2026, the company's premium positioning and deep integration into the property ecosystem give it substantial leverage to any improvement in listing volumes.

Bell Potter remains bullish. It has a buy rating and $244.00 price target on its shares, implying nearly 25% upside from current levels.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and REA Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough Friday session to end the week for investors.

Read more »

A young man looks like he his thinking holding his hand to his chin and gazing off to the side amid a backdrop of hand drawn lightbulbs that are lit up on a chalkboard.
Broker Notes

Brokers name 3 ASX shares to buy right now

Let's find out which shares top brokers are feeling bullish about this week.

Read more »

A smiling pink piggy bank graduates after years of growth.
Share Market News

Wilson Asset Management says CGT tax changes will 'redirect' investment toward yield

Fundie says income-producing assets are set to become 'comparatively more attractive'.

Read more »

A bored man sits at his desk, flat after seeing the latest news on the share market.
Share Fallers

Why Aeris, Newmont, PLS, and REA Group shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Share Gainers

Why A2 Milk, EOS, IDP Education, and SkyCity shares are charging higher today

These shares are ending the week in a positive session despite the market decline.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this red-hot ASX healthcare share keeps climbing

A 1,600% gain hasn't slowed this stock down.

Read more »

Close up portrait of happy businesswoman standing in front or leading her multi-ethnic corporate team.
Broker Notes

Morgans recommends these ASX shares as buys

Broker buy calls are not guarantees, but these three Morgans recommendations are worth a closer look.

Read more »

Man with a hand on his head looks at a red stock market chart showing a falling share price.
Share Market News

Why is the ASX 200 sinking to a 5 day low today?

The ASX 200 is under pressure as heavyweights fall.

Read more »